Language selection

Government of Canada / Gouvernement du Canada

Search

Universal Access to Contraception and Diabetes Medications and Increased Access to Diabetes Devices and Supplies, Canada-Manitoba Funding Agreement

Between: His Majesty the King in Right of Canada, as represented by the Minister of Health (hereinafter referred to as "Canada")

and: His Majesty the King in Right of the province of Manitoba, as represented by the Minister of Health, Seniors and Long-Term Care (hereinafter referred to as "Manitoba")

Canada and Manitoba are also referred to as a “Party” or collectively as the “Parties”.

Table of contents

Preamble

Whereas on October 10, 2024, the Pharmacare Act came into force, to guide efforts to improve, for all Canadians, the accessibility and affordability of prescription drugs and related products, and to support their appropriate use, in collaboration with the provinces, territories, Indigenous peoples and other partners and stakeholders, with the aim of continuing to work toward the implementation of national universal pharmacare;

Whereas pursuant to section 5 of the Pharmacare Act, the Government of Canada commits to maintaining long-term funding for provinces and territories to improve the accessibility and affordability of pharmaceutical products, primarily through agreements with their respective governments;

Whereas the Parties have agreed to targeted federal funding through an agreement, and pursuant to section 6 of the Pharmacare Act, the Minister of Health for Canada must make payments to Manitoba to enable it to provide Universal, Single-payer, First-dollar coverage for a range of contraception and diabetes prescription drugs and related products, and additionally, pursuant to the purpose of the Act, to enable Manitoba to improve coverage for diabetes devices and supplies;

Whereas the Minister of Health has the authority to enter into agreements with the provinces and territories, for the purpose of supporting activities provinces and territories will undertake to provide their Residents with Universal, Single-payer, First-dollar coverage for a range of contraception and diabetes prescription drugs and related products and to support Canadians’ improved access to diabetes devices and supplies; 

Whereas the Lieutenant Governor in Council authorized the Manitoba Minister of Health under the Executive Government Organization Act to enter into this Agreement with the Government of Canada under which Canada undertakes to provide funding toward costs incurred by Manitoba to provide its Residents with Universal, Single-payer, First-dollar coverage for a range of contraception and diabetes prescription drugs and related products and to support improved access to diabetes devices and supplies;

Whereas Manitoba has the primary responsibility for delivering health care services to its Residents, including coverage of pharmaceuticals; and supports diversity, equity, and the needs of underserved and/or disadvantaged populations, including, but not limited to First Nations, Inuit and Métis, official language minority communities, rural and remote communities, children, racialized communities (including Black Canadians), and 2SLGBTQI+;

Whereas notwithstanding anything in this Agreement, Residents of Manitoba who are enrolled in a federal drug benefit plan operated by Indigenous Services Canada (Non-Insured Health Benefit Plan), the Canadian Armed Forces (Canadian Armed Forces Drug Benefit Program), Veterans Affairs Canada (Treatment Benefits Program), Correctional Service Canada (Essential Health Services Framework) or Immigration, Refugees and Citizenship Canada (Interim Federal Health Program) will continue to receive benefits, including for drugs identified in this Agreement, through those plans;

And whereas Manitoba acknowledges the overall importance of meaningfully engaging and working with Indigenous organizations and governments responsible for the delivery of drug benefits to further support Universal, Single-payer, First-dollar coverage for a range of contraception and diabetes prescription drugs and related products and support access to diabetes devices and supplies;

Therefore, the Parties agree as follows:

1. Definitions

In this Agreement,

1.1. “Agreement” means this funding agreement and includes all annexes and any amendments made to this Agreement in accordance with section 8.;

1.2. “Diabetes Devices and Supplies” means those products identified by Manitoba as those that people with diabetes require to manage their condition or administer their medication;

1.3. "Eligible Expenditures" means the costs described in section 4.8. of this Agreement that are incurred and paid by Manitoba in carrying out the Initiative;

1.4. “First-dollar” refers to coverage where the products that are covered in Manitoba and belong to the categories identified in Annex A are made available at no cost to the Resident at the point of sale, subject to the conditions of coverage noted in Annex A. Costs include: deductibles, copays, premiums, and other items as recognized by Manitoba including but not limited to pharmacy or dispensing fees, and wholesale or distribution costs;

1.5. “Fiscal Year” means the twelve-month period beginning April 1st of any year and ending March 31st of the following year, and including parts thereof in the event that this Agreement commences after April 1st or expires or terminates before March 31st;

1.6. “Implementation Date” means the date upon which Universal, Single-payer, First-dollar coverage for the list of products that are covered in Manitoba and belong to the categories identified in Annex A is made available to Residents of Manitoba;

1.7. “Initiative” means funding made available to Manitoba for the activities under Stream 1 and Stream 2 of the Agreement;

1.8. “Resident” means a person who is registered and eligible for benefits under Manitoba’s Health Services Insurance Act. For greater certainty, Residents who are enrolled in a federal drug benefit plan will continue to receive coverage of the products that are covered in Manitoba and belong to the categories identified in Annex A from those plans;

1.9. “Savings” means the amount that Residents of Manitoba would otherwise have paid out-of-pocket or through a third-party payer for Diabetes Devices and Supplies if they purchased them prior to this Initiative;

1.10. “Single-payer” refers to coverage where the cost of products that are covered in Manitoba and belong to the categories identified in Annex A, are made available to Residents and are paid for entirely by the Government of Manitoba;

1.11. “Universal” refers to coverage where the products that are covered in Manitoba and belong to the categories identified in Annex A, are made available to all Residents of Manitoba.

2. Objectives

2.1. The Parties agree that with financial support from Canada, Manitoba will:

  1. Stream 1: Provide Universal, Single-payer, First-dollar coverage for the list of products that are covered in Manitoba and belong to the categories identified in Annex A;
  2. Stream 2: Increase access to insulin pumps and advanced glucose monitors (AGM) by expanding eligibility for public coverage of these products, as well as other activities that may be determined over the course of the agreement.

3. Term of Agreement

3.1. This Agreement will come into effect on the date the last party has signed and will end on March 31, 2029, unless terminated earlier in accordance with section 10 of this Agreement.

3.2. This Agreement covers:

  1. Eligible Expenditures incurred under section 4.8.b., 4.8.c. and 4.8.d. from the date it comes into effect until March 31, 2029.
  2. Eligible Expenditures incurred under section 4.8.a. and 4.8.e. from the Implementation Date until March 31, 2029.

3.3. Manitoba’s Implementation Date will be April 15, 2025.

4. Financial contribution and obligations

4.1. Allocation to Manitoba

4.1.1. Stream 1:

The maximum amounts to be transferred to Manitoba over 4 years are:

4.1.2. Stream 2:

The amount of $9,945,348 is to be transferred to Manitoba in Fiscal Year 2025-2026.

4.2. Payments

Canada’s contribution will be paid as follows:

4.2.1. Stream 1:

For Fiscal Year 2025-2026, Manitoba will receive an initial payment equal to 50% of the annual amount determined in section 4.1.1. on or about June 2, 2025, and a second payment equal to the balance of Canada’s contribution to Manitoba on or about November 15, 2025.

For each subsequent Fiscal Year, Manitoba will receive semi-annual payments. The first payment will be paid on or about April 15 and will equal 50% of the annual amount determined in section 4.1.1. The second payment will be paid on or about November 15 and will equal the balance of Canada‘s contribution to Manitoba for the given Fiscal Year.

4.2.2. Stream 2:

Manitoba will receive the full amount identified in section 4.1.2. as a one-time payment on or about November 15, 2025, or, within fifteen (15) business days of the Implementation Date, whichever is later.

4.3. Adjustment

Notwithstanding any other provisions of this Agreement, Canada may withhold or reduce any payments to Manitoba pursuant to this Agreement, as follows, in the event that:

  1. Manitoba has failed to make Universal, Single-payer, First-dollar coverage for the list of products that are covered in Manitoba and belong to the categories identified in Annex A available to its Residents for any period following the Implementation Date: for each day this occurs, Canada will withhold or reduce an equal daily share of Stream 1 funding;
  2. Manitoba’s 2022-23 Stream 1 spending reported in Annex B is greater than the amount reported under section 4.9.1.c.i.: Canada will withhold or reduce an amount equivalent to the difference between these two amounts, not exceeding the amount of funding received from Canada spent by Manitoba on product costs (4.9.1.b.i.) in the Fiscal Year;
  3. Manitoba’s 2022-23 Stream 2 spending reported in Annex B is greater than the amount reported under section 4.9.1.c.ii.: Canada will withhold or reduce an amount equivalent to the difference between these two amounts, not exceeding the amount of funding received from Canada spent by Manitoba on product costs (4.9.1.b.iii.) in the Fiscal Year;
  4. Manitoba has not submitted reports in accordance with the requirements set out in sections 4.9. and 4.10.

4.4. Overpayments

In the event payments made exceed the amount to which Manitoba is entitled under this Agreement, the amount of the excess is a debt due to Canada and, unless otherwise agreed to in writing by the Parties, Manitoba shall repay the amount within sixty (60) calendar days of written notice from Canada. 

4.5. Retaining funds

4.5.1. Stream 1:

  1. For Fiscal Years 2025-26, 2026-27, and 2027-28, Manitoba may retain and carry forward to the next Fiscal Year the amount of up to 10% of the contribution paid to Manitoba for a Fiscal Year (4.1.1.) that is in excess of the amount of funding received from Canada that Manitoba spent on Eligible Expenditures for Stream 1 during the Fiscal Year (4.9.1.b.i. and ii.).
  2. Any request by Manitoba to retain and carry forward an amount exceeding 10% for any given Fiscal Year will be subject to Canada’s approval, which will be evidenced in writing by the designated official, at the Assistant Deputy Minister level.

4.5.2. Stream 2:

  1. For Fiscal Year 2025-26, upon request, Manitoba may retain and carry forward to the next Fiscal Year the amount of up to 75% of the contribution paid to Manitoba as per 4.1.2.
  2. For Fiscal Year 2026-27, upon request, Manitoba may retain and carry forward to the next Fiscal Year the amount of up to 50% of the contribution paid to Manitoba as per 4.1.2.
  3. For Fiscal Year 2027-28, upon request, Manitoba may retain and carry forward to the next Fiscal Year the amount of up to 25% of the contribution paid to Manitoba as per 4.1.2.

4.5.3. All retained funds as per 4.5.1. and 4.5.2. are subject to monitoring and reporting to Canada on the management and spending of the funds carried forward.

4.6. Underspending

One hundred and twenty (120) calendar days before March 31 for any given Fiscal Year, Manitoba shall inform Canada in writing of any potential underspending with regard to Stream 1 and/or Stream 2. Manitoba shall indicate:

  1. Stream 1: the difference between the Fiscal Year contribution from Canada provided under section 4.1.1. and the sum of federal funding to be spent in the Fiscal Year on Stream 1 product costs and other Eligible Expenditures (4.9.1.b.i. + 4.9.1.b.ii.);
  2. Stream 2: the difference between the contribution from Canada provided under section 4.1.2. and the cumulative sum of federal funding to be spent on Stream 2 product costs and other Eligible Expenditures (4.9.1.b.iii. + 4.9.1.b.iv.).

4.7. Funding subject to appropriation and Initiative funding authorities

  1. Notwithstanding any other provision of this Agreement, the amount of funding to be provided to Manitoba pursuant to this Agreement is subject to there being an appropriation of funds by the Parliament of Canada for the Fiscal Year in which any commitment would come due for payment.
  2. In the event that authorities for the Initiative are amended or terminated, or if funding levels are reduced or cancelled by the Parliament of Canada for any Fiscal Year in which a payment is to be made under this Agreement, Canada may reduce or terminate any further payments to be made under this Agreement.
  3. Where funding under this Agreement is to be reduced or terminated, Canada shall provide Manitoba with at least one hundred and twenty (120) calendar days written notice of the reduction or termination and shall reimburse Manitoba for any Eligible Expenditures incurred up to the date upon which the reduction/termination is to take effect.

4.8. Eligible Expenditures

Manitoba will use funding under this Agreement only for Eligible Expenditures that support the objectives of the Initiative and are directly related to the activities set out herein. Eligible Expenditures include:

  1. Product costs – including:
    1. Stream 1:
      Costs paid by Manitoba on behalf of its Residents for the products that are covered in Manitoba and belong to the categories identified in Annex A, inclusive of the product cost, any applicable markups, and any associated dispensing fees as recognized by Manitoba’s public plan;
    2. Stream 2:
      Costs paid by Manitoba on behalf of its Residents for the Diabetes Devices and Supplies outlined in 2.1.b., inclusive of the product cost, any applicable markups, and any associated dispensing fees as recognized by Manitoba’s public plan;
  2. Costs related to implementing changes to or creating new public coverage plans (e.g., planning, administrative, and communication activities) for the purpose of delivering the commitments in this Agreement;
  3. Operating costs related to delivering the commitments in this Agreement, including: salaries and benefits, contractual personnel, honoraria, training and professional development, travel and accommodation, materials and supplies, equipment, and rent and utilities;
  4. Information technology and related investments related to delivering the commitments in this Agreement, including enhancement of data collection, analysis, and sharing capacity; and
  5. Costs related to activities associated with evaluation and reporting obligations on the commitments in this Agreement.

4.9. Reporting on expenditures

Beginning in Fiscal Year 2026-27, as a condition of annual funding under this Agreement, by October 1 of each Fiscal Year, Manitoba agrees to provide Canada with an attested financial statement as outlined in section 4.9.1, in respect of the preceding Fiscal Year.

4.9.1. The financial statement shall show:

  1. The total amount of funding received from Canada under this Agreement during the Fiscal Year;
  2. The total amount of funding received from Canada spent during the Fiscal Year by Manitoba on behalf of its Residents on:

    Stream 1:
    i. Product costs (4.8.a.i.);
    ii. Eligible Expenditures related to 4.8.a.i., as per 4.8.b. to 4.8.e.

    Stream 2:
    iii. Product costs (4.8.a.ii.);
    iv. Eligible Expenditures related to 4.8.a.ii., as per 4.8.b. to 4.8.e.

  3. The total amount of funding from sources other than Canada spent during the Fiscal Year by Manitoba on behalf of its Residents on:

    Stream 1:
    i. Product costs (4.8.a.i.);

    Stream 2:
    i. Product costs (4.8.a.ii.).

  4. If applicable, the amount of any funding carried forward under section 4.5.

4.10. Reporting on results

Beginning in Fiscal Year 2026-27, as a condition of annual funding under this Agreement, by October 1 of each Fiscal Year, Manitoba agrees to report to Canada the amount of Savings delivered to Manitoba Residents as a result of the measures taken to improve access to Diabetes Devices and Supplies under this Agreement (per section 2.1.b.), in respect of the preceding Fiscal Year.

4.11. Audit

Manitoba will ensure that expenditure information presented in the annual financial statement is, in accordance with Manitoba’s standard accounting practices, complete and accurate.

4.12. Evaluation

Responsibility for evaluating the Initiative rests with Manitoba in accordance with its own evaluation policies and practices.

5. Additional coverage improvements

5.1. Manitoba will provide free public coverage of hormone replacement therapy for all Residents.

6. Communications

6.1. The Parties agree on the importance of communicating with the public about the objectives of this Agreement in an open, transparent, effective, and proactive manner through appropriate public information activities. The Parties agree to coordinate their efforts on public communications related to this Agreement to ensure consistency in messaging.

6.2. The Parties will each receive the appropriate credit and visibility when investments financed through this Agreement are announced to the public.

6.3. In the spirit of transparency and open government, Manitoba and Canada will make this Agreement, including any amendments, and subject to section 9.4., publicly available on a Government of Canada website.

6.4. With regard to Universal, Single-payer, First-dollar coverage for the list of products that are covered in Manitoba and belong to the categories identified in Annex A, no later than Manitoba’s Implementation Date, Manitoba commits to publish on its website which prescription drugs and related products are included under the coverage and how Residents can access the coverage.

6.5. With regard to increasing access to Diabetes Devices and Supplies outlined in section 2.1.b., no later than Manitoba’s receipt of the one-time payment for Stream 2 defined in section 4.2.2., Manitoba commits to publish on its website how the Stream 2 funding outlined in section 4.1.2. will be used to increase access to Diabetes Devices and Supplies for its Residents.

6.6. Canada, with prior notice to Manitoba, may incorporate all or any part or parts of the data and information in sections 4.9. and 4.10., or any parts of evaluation and audit reports made public by Manitoba into any report that Canada may prepare for its own purposes, including any reports to the Parliament of Canada or reports that may be made public.

6.7. The Parties reserve the right to conduct public communications, announcements, events, outreach and promotional activities with regard to this Agreement, and, where feasible, to give ten (10) business days advance notice and advance copies of public communications related to this Agreement, and results of the investments of this Agreement.

7. Dispute resolution

7.1. The Parties are committed to working together and avoiding disputes through government-to-government information exchange, advance notice, early consultation, and discussion, clarification, and resolution of issues, as they arise.

7.2. If at any time either Party is of the opinion that the other Party has failed to comply with any of its obligations or undertakings under this Agreement or is in breach of any term or condition of this Agreement, that Party may notify the other party in writing of the failure or breach. Upon such notice, the Parties will endeavour to resolve the issue and dispute bilaterally through their designated officials, at the Assistant Deputy Minister level.

7.3. If a dispute cannot be resolved by the designated officials, at the Assistant Deputy Minister level, then the dispute will be referred to the Deputy Ministers of the Parties responsible for health, and if it cannot be resolved by them, then the respective Ministers of Canada and Manitoba, most responsible for health, shall endeavour to resolve the dispute.

8. Amendments to the Agreement

8.1. The main text of this Agreement may be amended at any time by mutual consent of the Parties. Any amendments shall be in writing and signed, in the case of Canada, by Canada's Minister of Health, and in the case of Manitoba, by Manitoba's Minister of Health, Seniors and Long-Term Care.

8.2. Annexes to this Agreement may be amended at any time by mutual consent of the Parties. Any amendments to the Annexes shall be in writing and signed by both Parties’ designated officials, as denoted in section 11.

9. General

9.1. Governing laws

This Agreement shall be governed by, interpreted and enforced in accordance with the laws in force in Manitoba and the laws of Canada applicable therein.

9.2. Entire Agreement

This Agreement, including its preamble and annexes, sets forth the entire Agreement between the Parties with respect to its subject matter and supersedes and cancels all prior agreements, understandings, negotiations and discussions, both oral and written, between the Parties with respect to the Initiative.

9.3. Members of Parliament

No member of the House of Commons or Senate or of the Legislature of Manitoba shall be admitted to any share or part of this Agreement or to any benefit arising from it that is not otherwise available to the general public.

9.4. Personal and confidential information

The Parties shall comply with applicable laws, contractual obligations, and policies pertaining to privacy and confidentiality in dealing with information and records related to the Initiative.

9.5. Official languages

Manitoba agrees to consider how they can support Canada’s official languages and the needs of official language minority communities in the implementation of this Agreement.

9.6. Diverse populations

Manitoba agrees to consider how they can support diverse populations based on identity factors such as sex, gender, age, disability, Indigeneity, sexual orientation, ethnicity, religion and more in the implementation of this Agreement.

10. Terminating the Agreement

10.1. Either Party may terminate this Agreement at any time if the terms of this Agreement are breached by the other Party by giving at least six (6) months written notice of its intention to terminate.

10.2. As of the effective date of termination of this Agreement, Canada shall have no obligation to make any further payments.

10.3. All obligations under this Agreement shall expressly, or by their nature, survive termination or expiration of this Agreement until, and unless, they are fulfilled, or by their nature expire.

11. Notice

Communications, including reporting and any notice, information, document, request or other communication, shall be in writing and sent to the coordinates below. Communications that are delivered in person shall be deemed to have been received upon delivery; communications transmitted by facsimile or by e-mail shall be deemed to have been received one (1) business day after having been sent; and communications that are sent by mail shall be deemed to have been received eight (8) business days after being mailed.

Any notice to Canada shall be addressed to:

Assistant Deputy Minister, Health Policy Branch
Health Canada
70 Colombine Driveway, Tunney's Pasture
Brooke Claxton Building
Ottawa, Ontario
K1A 0K9
Email: hpb.assistant.deputy.minister-dgps.sous-ministre.adjointes@hc-sc.gc.ca

Any notice to Manitoba shall be addressed to:

Assistant Deputy Minister
Insurance Division, Manitoba Health, Seniors and Long-Term Care
300 Carlton Street
Winnipeg, Manitoba
R3B 3M9
Email: admoinsurance@gov.mb.ca

12. Signing in counterpart

This Agreement may be signed in counterparts and each counterpart shall constitute an original document; these counterparts taken together shall constitute one and the same Agreement.

In witness whereof, this Agreement is duly executed by the authorized representatives of the Parties.

Signed on behalf of Canada by the Minister of Health at, this day of, 2025.

The Honourable Mark Holland, Minister of Health

In witness whereof, this Agreement is duly executed by the authorized representatives of the Parties.

Signed on behalf of Manitoba by the Minister of Health, Seniors and Long-Term Care at, this day of, 2025.

The Honourable Uzoma Asagwara, Minister of Health, Seniors and Long-Term Care

Annex A – List of prescription drugs and related products for which Manitoba will provide universal, single-payer, first-dollar coverage

Table 1A: Diabetes
Drug/related product categories
(active ingredient)		 Conditions of coverage
(Open benefitFootnote 1 unless otherwise specified)

fast-acting insulin regular (human)

n/aFootnote 2

fast-acting insulin (pork)

 n/a

fast-acting insulin lispro

 n/a

fast-acting insulin aspart

 n/a

fast-acting insulin glulisine

 n/a

intermediate-acting insulin human isophane

 n/a

intermediate-acting insulin (pork)

 n/a

insulin regular (human) and insulin isophane NPH blend

n/a

insulin lispro and insulin lispro protamine blend

 n/a

long-acting insulin glargine

 n/a

long-acting insulin detemir

 n/a

metformin

Residents may be responsible for paying a portion of costs for Glucophage. Other free options are available.

glyburide (glibenclamide)

Residents may be responsible for paying a portion of costs for Diabeta-Glyburide. Other free options are available.

gliclazide

Residents may be responsible for paying a portion of costs for Diamicron. Other free options are available.

saxagliptin and metformin

Exception Drug Status (EDS)Footnote 3 benefit

empagliflozin and metformin

Exception Drug Status (EDS) benefit

linagliptin and metformin

Exception Drug Status (EDS) benefit

dapagliflozin

Residents may be responsible for paying a portion of costs for Forxiga. Other free options are available.
Table 1B: Diabetes – Additional
Drug/related product categories
(active ingredient)		 Conditions of coverage
(Open benefitFootnote 1 unless otherwise specified)

insulin lispro and insulin lispro protamine

 n/aFootnote 2

long-acting insulin degludec

 n/a

glimepiride

Exception Drug Status (EDS)Footnote 3 benefit

dapagliflozin and metformin

Residents may be responsible for paying a portion of costs for Xigduo. Other free options are available.

sitagliptin and metformin

Exception Drug Status (EDS) benefit;
Residents may be responsible for paying a portion of costs for Janumet. Other free options are available.

acarbose

 n/a

rosiglitazone

n/a

pioglitazone

Exception Drug Status (EDS) benefit

sitagliptin

Exception Drug Status (EDS) benefit;
Residents may be responsible for paying a portion of costs for Januvia. Other free options are available.

saxagliptin

Exception Drug Status (EDS) benefit;
Residents may be responsible for paying a portion of costs for Onglyza. Other free options are available.

linagliptin

Exception Drug Status (EDS) benefit

lixisenatide with insulin glargine

Exception Drug Status (EDS) benefit

empagliflozin

Exception Drug Status (EDS) benefit

canagliflozin

Exception Drug Status (EDS) benefit

repaglinide

Exception Drug Status (EDS) benefit;
Residents may be responsible for paying a portion of costs for Gluconorm. Other free options are available.

glucagon

 n/a
Table 2A: Contraception
Drug/related product categories
(active ingredient)		 Conditions of coverage
(Open benefitFootnote 1 unless otherwise specified)

levonorgestrel and ethinylestradiol

Residents may be responsible for paying a portion of costs for Alesse, Min-Ovral. Other free options are available.

desogestrel and ethinylestradiol

Residents may be responsible for paying a portion of costs for Marvelon. Other free options are available.

drospierenone and ethinylestradiol

Residents may be responsible for paying a portion of costs for Mya, Yasmin. Other free options are available.

norethindrone and ethinylestradiol

 n/aFootnote 2

levonorgestrel and ethinylestradiol

 n/a

norethindrone and ethinylestradiol

 n/a

norgestimate and ethinylestradiol

 n/a

norethindrone

 n/a

medroxyprogesterone

 n/a

etonogestrel

 n/a

levonorgestrel

Maximum of 3 treatments (3 tablets) per benefit year

plastic IUD with copper

Coverage provided through public health programming

plastic IUD with progestogen

 n/a

vaginal ring with etonogestrel and ethinyl estradiolFootnote 4

See note

Table 2B: Contraception – Additional
Drug/related product categories
(active ingredient)		 Conditions of coverage
(Open benefitFootnote 1 unless otherwise specified)
drospirenone n/aFootnote 2

Annex B – Fiscal year 2022-23 spending by the Government of Manitoba on stream 1 and stream 2 product costs

Stream 1

For the prescription drugs and related products included in Annex A, the amount of Fiscal Year 2022-23 spending by the Government of Manitoba was:

Prescription drugs and related products 2022-23 spending
Diabetes $23,195,236

Contraception

 $750,746
Total $23,945,982

Stream 2

For the Diabetes Devices and Supplies outlined in section 2.1.b., the amount of Fiscal Year 2022-23 spending by the Government of Manitoba was:

Diabetes devices and supplies 2022-23 spending
Insulin Pumps and Advanced Glucose Monitors $1,449,593

Note

Spending includes cost of the drugs/related products/devices/supplies (inclusive of the product cost, any applicable markups, and any associated dispensing fees) if paid for by a public plan in your jurisdiction.

Spending does not include any portion of the above costs paid by the patient and not reimbursed by a public plan in your jurisdiction (i.e., flat fee, copay, deductible).

Footnotes

Footnote 1

Open benefit: the drug or related product is an eligible benefit in all prescribed circumstances.

Return to footnote 1 referrer

Footnote 2

Not applicable.

Return to footnote 2 referrer

Footnote 3

Exception Drug Status (EDS) benefit: the drug or related product is an eligible benefit only in Exception circumstances with prior approval from Manitoba.

Return to footnote 3 referrer

Footnote 4

Note: Manitoba will make best efforts to make this product (or an alternative) available over the course of the agreement.

Return to footnote 4 referrer

Page details

Date modified: